By activating the (protein kinase B) AKT/mTOR (mammalian target of rapamycin) pathway and promoting epithelial–mesenchymal transition (EMT), fibrinogen may simultaneously encourage hepatoma cell motility and invasion. This evidence concerns the gene MTOR and hepatocellular carcinoma.